PMID- 33058931
OWN - NLM
STAT- MEDLINE
DCOM- 20210920
LR  - 20231110
IS  - 1872-8294 (Electronic)
IS  - 0169-409X (Print)
IS  - 0169-409X (Linking)
VI  - 160
DP  - 2020
TI  - Lymphatic immunomodulation using engineered drug delivery systems for cancer 
      immunotherapy.
PG  - 19-35
LID - S0169-409X(20)30141-1 [pii]
LID - 10.1016/j.addr.2020.10.004 [doi]
AB  - Though immunotherapy has revolutionized the treatment of cancer to improve 
      disease outcomes, an array of challenges remain that limit wider clinical 
      success, including low rate of response and immune-related adverse events. 
      Targeting immunomodulatory drugs to therapeutically relevant tissues offers a way 
      to overcome these challenges by potentially enabling enhanced therapeutic 
      efficacy and decreased incidence of side effects. Research highlighting the 
      importance of lymphatic tissues in the response to immunotherapy has increased 
      interest in the application of engineered drug delivery systems (DDSs) to enable 
      specific targeting of immunomodulators to lymphatic tissues and cells that they 
      house. To this end, a variety of DDS platforms have been developed that enable 
      more efficient uptake into lymphatic vessels and lymph nodes to provide targeted 
      modulation of the immune response to cancer. This can occur either by delivery of 
      immunotherapeutics to lymphatics tissues or by direct modulation of the lymphatic 
      vasculature itself due to their direct involvement in tumor immune processes. 
      This review will highlight DDS platforms that, by enabling the activities of 
      cancer vaccines, chemotherapeutics, immune checkpoint blockade (ICB) antibodies, 
      and anti- or pro-lymphangiogenic factors to lymphatic tissues through directed 
      delivery and controlled release, augment cancer immunotherapy.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Manspeaker, Margaret P
AU  - Manspeaker MP
AD  - School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, 
      Atlanta, GA, United States of America; Parker H. Petit Institute for 
      Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA, 
      United States of America.
FAU - Thomas, Susan N
AU  - Thomas SN
AD  - Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of 
      Technology, Atlanta, GA, United States of America; George W. Woodruff School of 
      Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA, United 
      States of America; Wallace H. Coulter Department of Biomedical Engineering, 
      Georgia Institute of Technology and Emory University, Atlanta, GA, United States 
      of America; Winship Cancer Institute, Emory University School of Medicine, 
      Atlanta, GA, United States of America. Electronic address: 
      susan.thomas@gatech.edu.
LA  - eng
GR  - F31 CA150523/CA/NCI NIH HHS/United States
GR  - R01 CA207619/CA/NCI NIH HHS/United States
GR  - R01 CA247484/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Systematic Review
DEP - 20201012
PL  - Netherlands
TA  - Adv Drug Deliv Rev
JT  - Advanced drug delivery reviews
JID - 8710523
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Drug Implants)
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0 (Lipids)
RN  - 0 (Proteins)
SB  - IM
MH  - Adjuvants, Immunologic
MH  - Angiogenesis Inhibitors/administration & dosage/pharmacology
MH  - Antineoplastic Agents, Immunological/*administration & 
      dosage/*pharmacology/therapeutic use
MH  - Cancer Vaccines/administration & dosage
MH  - Delayed-Action Preparations
MH  - Drug Delivery Systems/*methods
MH  - Drug Implants/chemistry
MH  - Humans
MH  - Immune Checkpoint Inhibitors/administration & dosage/pharmacology
MH  - Immunomodulation/*physiology
MH  - Lipids/chemistry
MH  - Lymph Nodes/physiology
MH  - Lymphatic Vessels/physiology
MH  - Nanoparticles
MH  - Neoplasms/*drug therapy/prevention & control
MH  - Proteins/chemistry
MH  - Tissue Scaffolds/chemistry
PMC - PMC7736326
MID - NIHMS1641331
OTO - NOTNLM
OT  - Controlled release
OT  - Drug delivery system
OT  - Immunoengineering
OT  - Lymph node
OT  - Lymphatics
OT  - Tumor immunotherapy
COIS- Declaration of Competing Interest None.
EDAT- 2020/10/16 06:00
MHDA- 2021/09/21 06:00
PMCR- 2021/10/12
CRDT- 2020/10/15 20:09
PHST- 2020/05/29 00:00 [received]
PHST- 2020/10/01 00:00 [revised]
PHST- 2020/10/07 00:00 [accepted]
PHST- 2020/10/16 06:00 [pubmed]
PHST- 2021/09/21 06:00 [medline]
PHST- 2020/10/15 20:09 [entrez]
PHST- 2021/10/12 00:00 [pmc-release]
AID - S0169-409X(20)30141-1 [pii]
AID - 10.1016/j.addr.2020.10.004 [doi]
PST - ppublish
SO  - Adv Drug Deliv Rev. 2020;160:19-35. doi: 10.1016/j.addr.2020.10.004. Epub 2020 
      Oct 12.